Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

FDA grants approval to brentuximab vedotin with lenalidomide plus rituximab for relapsed/refractory LBCL

On February 11, 2025, the U.S. Food and Drug Administration (FDA) granted approval to brentuximab vedotin (BV) combined with lenalidomide…

Read More

FDA approves acalabrutinib with bendamustine and rituximab for previously untreated MCL

On January 16, 2025, the U.S. Food and Drug Administration (FDA) approved acalabrutinib, a Bruton’s tyrosine kinase (BTK) inhibitor, in…

Read More

ASH 2024 Press Briefing Rundown: Diagnosing and Treating Blood Cancers and “Almost Cancers”

VJHemOnc is thrilled to bring you the latest updates from the 66th American Society of Hematology (ASH) Annual Meeting and…

Read More

ASH 2024 press briefing rundown: treating not-so-benign hematology conditions

VJHemOnc is thrilled to bring you the latest updates from the 66th American Society of Hematology (ASH) Annual Meeting and…

Read More

ASH 2024: Late-breaking abstract rundown

VJHemOnc is excited to share a feature on the late-breaking abstracts presented at the 66th ASH Annual Meeting in Exposition.

Read More

Spotlight on Prolonging Remission in AML: Case Study

Read More

FDA approves revumenib for R/R acute leukemia with KMT2A translocation

On November 15, 2024, the U.S. Food and Drug Administration (FDA) granted approval to the menin inhibitor revumenib for adult…

Read More

FDA grants approval to obecabtagene autoleucel for relapsed/refractory adult B-cell acute lymphoblastic leukemia

On November 8, 2024, the U.S. Food and Drug Administration (FDA) granted the approval of obecabtagene autoleucel (obe-cel) for adult…

Read More

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals